EUSA acquires global rights to Janssen's Sylvant for $115mm
EUSA Pharma acquired worldwide rights to Sylvant (siltuximab) from Janssen Sciences Ireland UC.
- Specialty Pharmaceuticals
- Large Molecule
- Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com